HEADER HYDROLASE/HYDROLASE INHIBITOR 06-JUL-10 3NU3 TITLE WILD TYPE HIV-1 PROTEASE WITH ANTIVIRAL DRUG AMPRENAVIR COMPND MOL_ID: 1; COMPND 2 MOLECULE: PROTEASE; COMPND 3 CHAIN: A, B; COMPND 4 FRAGMENT: RESIDUES 501-599; COMPND 5 EC: 3.4.23.16; COMPND 6 ENGINEERED: YES; COMPND 7 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HUMAN IMMUNODEFICIENCY VIRUS 1; SOURCE 3 ORGANISM_TAXID: 11676; SOURCE 4 GENE: GAG, POL; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 6 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 9 EXPRESSION_SYSTEM_PLASMID: PET11A KEYWDS ENZYME INHIBITION, ASPARTIC PROTEASE, HIV/AIDS, CONFORMATIONAL KEYWDS 2 CHANGE, AMPRENAVIR, HYDROLASE, HYDROLASE-HYDROLASE INHIBITOR COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR Y.-F.WANG,A.Y.KOVALEVSKY,I.T.WEBER REVDAT 3 24-NOV-10 3NU3 1 JRNL REVDAT 2 08-SEP-10 3NU3 1 JRNL REVDAT 1 25-AUG-10 3NU3 0 JRNL AUTH C.H.SHEN,Y.F.WANG,A.Y.KOVALEVSKY,R.W.HARRISON,I.T.WEBER JRNL TITL AMPRENAVIR COMPLEXES WITH HIV-1 PROTEASE AND ITS JRNL TITL 2 DRUG-RESISTANT MUTANTS ALTERING HYDROPHOBIC CLUSTERS. JRNL REF FEBS J. V. 277 3699 2010 JRNL REFN ISSN 1742-464X JRNL PMID 20695887 JRNL DOI 10.1111/J.1742-4658.2010.07771.X REMARK 2 REMARK 2 RESOLUTION. 1.02 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-97 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.02 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 10.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 95.5 REMARK 3 CROSS-VALIDATION METHOD : FREE R REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.124 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.123 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.142 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 5665 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : NULL REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : 0.117 REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : 0.116 REMARK 3 FREE R VALUE (F>4SIG(F)) : 0.134 REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : 4993 REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 99976 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1512 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 51 REMARK 3 SOLVENT ATOMS : 291 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : 1754.29 REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : 1636.00 REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : 53 REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 19506 REMARK 3 NUMBER OF RESTRAINTS : 28566 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.017 REMARK 3 ANGLE DISTANCES (A) : 0.036 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : 0.000 REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : 0.031 REMARK 3 ZERO CHIRAL VOLUMES (A**3) : 0.099 REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : 0.089 REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : 0.041 REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : 0.006 REMARK 3 SIMILAR ADP COMPONENTS (A**2) : 0.035 REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : 0.077 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: NULL REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH & HUBER REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: CONJUGAGE GRADIENT MINIMIZATION REMARK 4 REMARK 4 3NU3 COMPLIES WITH FORMAT V. 3.20, 01-DEC-08 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 13-JUL-10. REMARK 100 THE RCSB ID CODE IS RCSB060281. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 15-MAR-07 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 5.6 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 22-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.8 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : MARMOSAIC 300 MM CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 113536 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.020 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 95.5 REMARK 200 DATA REDUNDANCY : 6.800 REMARK 200 R MERGE (I) : 0.05700 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.02 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.06 REMARK 200 COMPLETENESS FOR SHELL (%) : 62.6 REMARK 200 DATA REDUNDANCY IN SHELL : 3.00 REMARK 200 R MERGE FOR SHELL (I) : 0.38300 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.600 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: 2QCI REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 54.42 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.70 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: CRYSTAL WAS GROWN BY THE HANGING-DROP REMARK 280 VAPOR-DIFFUSION METHOD AT ROOM TEMPERATURE, FROM A 2.2 MG/ML REMARK 280 PROTEIN SOLUTION AT PH 5.6 WITH 0.1M MES AND 0.6-0.8M SODIUM REMARK 280 CHLORIDE. THE INHIBITOR WAS MIXED WITH PROTEASE IN A RATIO 5:1, REMARK 280 VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z REMARK 290 3555 -X+1/2,Y+1/2,-Z REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 29.05350 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 42.98550 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 29.05350 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 42.98550 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 3630 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 9850 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -22.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 GLU A 21 OE1 - CD - OE2 ANGL. DEV. = 7.3 DEGREES REMARK 500 ASP A 30 CB - CG - OD2 ANGL. DEV. = -7.0 DEGREES REMARK 500 ARG A 41 CD - NE - CZ ANGL. DEV. = 14.5 DEGREES REMARK 500 ARG A 41 NE - CZ - NH1 ANGL. DEV. = 7.3 DEGREES REMARK 500 ARG A 57 CD - NE - CZ ANGL. DEV. = 13.2 DEGREES REMARK 500 LYS B 143 CA - CB - CG ANGL. DEV. = 16.6 DEGREES REMARK 500 LYS B 143 CD - CE - NZ ANGL. DEV. = 29.0 DEGREES REMARK 500 ARG B 157 NE - CZ - NH1 ANGL. DEV. = 3.4 DEGREES REMARK 500 ARG B 157 NE - CZ - NH2 ANGL. DEV. = -3.6 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 525 REMARK 525 SOLVENT REMARK 525 REMARK 525 THE SOLVENT MOLECULES HAVE CHAIN IDENTIFIERS THAT REMARK 525 INDICATE THE POLYMER CHAIN WITH WHICH THEY ARE MOST REMARK 525 CLOSELY ASSOCIATED. THE REMARK LISTS ALL THE SOLVENT REMARK 525 MOLECULES WHICH ARE MORE THAN 5A AWAY FROM THE REMARK 525 NEAREST POLYMER CHAIN (M = MODEL NUMBER; REMARK 525 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE REMARK 525 NUMBER; I=INSERTION CODE): REMARK 525 REMARK 525 M RES CSSEQI REMARK 525 HOH A1145 DISTANCE = 6.73 ANGSTROMS REMARK 525 HOH A1185 DISTANCE = 6.72 ANGSTROMS REMARK 525 HOH B1255 DISTANCE = 6.62 ANGSTROMS REMARK 620 REMARK 620 METAL COORDINATION REMARK 620 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 620 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 NA A 501 NA REMARK 620 N RES CSSEQI ATOM REMARK 620 1 ASP A 60 O REMARK 620 2 HOH A1128 O 97.4 REMARK 620 3 HOH A1131 O 97.1 94.7 REMARK 620 4 HOH A1129 O 98.7 71.5 160.2 REMARK 620 5 HOH A1130 O 74.3 169.9 92.0 103.7 REMARK 620 6 HOH A1132 O 172.9 87.9 77.7 87.5 100.8 REMARK 620 N 1 2 3 4 5 REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE NA A 501 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL A 512 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 478 B 401 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL B 511 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE CL B 513 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL B 801 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC7 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL B 802 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2IEN RELATED DB: PDB REMARK 900 WILD TYPE HIV-1 PROTEASE WITH ANTIVIRAL DRUG DARUNAVIR REMARK 900 RELATED ID: 3NU4 RELATED DB: PDB REMARK 900 MUTANT V32I HIV-1 PROTEASE WITH ANTIVIRAL DRUG AMPRENAVIR REMARK 900 RELATED ID: 3NU5 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANT I50V WITH REMARK 900 ANTIVIRAL DRUG AMPRENAVIR REMARK 900 RELATED ID: 3NU6 RELATED DB: PDB REMARK 900 MUTANT I54M HIV-1 PROTEASE WITH ANTIVIRAL DRUG AMPRENAVIR REMARK 900 RELATED ID: 3NUJ RELATED DB: PDB REMARK 900 MUTANT I54V HIV-1 PROTEASE WITH ANTIVIRAL DRUG AMPRENAVIR REMARK 900 RELATED ID: 3NU9 RELATED DB: PDB REMARK 900 MUTANT I84V HIV-1 PROTEASE WITH ANTIVIRAL DRUG AMPRENAVIR REMARK 900 RELATED ID: 3NUO RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HIV-1 PROTEASE MUTANT L90M WITH REMARK 900 ANTIVIRAL DRUG AMPRENAVIR DBREF 3NU3 A 1 99 UNP P03366 POL_HV1B1 501 599 DBREF 3NU3 B 101 199 UNP P03366 POL_HV1B1 501 599 SEQADV 3NU3 LYS A 7 UNP P03366 GLN 507 ENGINEERED MUTATION SEQADV 3NU3 ILE A 33 UNP P03366 LEU 533 ENGINEERED MUTATION SEQADV 3NU3 ILE A 63 UNP P03366 LEU 563 ENGINEERED MUTATION SEQADV 3NU3 ALA A 67 UNP P03366 CYS 567 ENGINEERED MUTATION SEQADV 3NU3 ALA A 95 UNP P03366 CYS 595 ENGINEERED MUTATION SEQADV 3NU3 LYS B 107 UNP P03366 GLN 507 ENGINEERED MUTATION SEQADV 3NU3 ILE B 133 UNP P03366 LEU 533 ENGINEERED MUTATION SEQADV 3NU3 ILE B 163 UNP P03366 LEU 563 ENGINEERED MUTATION SEQADV 3NU3 ALA B 167 UNP P03366 CYS 567 ENGINEERED MUTATION SEQADV 3NU3 ALA B 195 UNP P03366 CYS 595 ENGINEERED MUTATION SEQRES 1 A 99 PRO GLN ILE THR LEU TRP LYS ARG PRO LEU VAL THR ILE SEQRES 2 A 99 LYS ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 A 99 GLY ALA ASP ASP THR VAL ILE GLU GLU MET SER LEU PRO SEQRES 4 A 99 GLY ARG TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 A 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE ILE ILE GLU SEQRES 6 A 99 ILE ALA GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 A 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 A 99 GLN ILE GLY ALA THR LEU ASN PHE SEQRES 1 B 99 PRO GLN ILE THR LEU TRP LYS ARG PRO LEU VAL THR ILE SEQRES 2 B 99 LYS ILE GLY GLY GLN LEU LYS GLU ALA LEU LEU ASP THR SEQRES 3 B 99 GLY ALA ASP ASP THR VAL ILE GLU GLU MET SER LEU PRO SEQRES 4 B 99 GLY ARG TRP LYS PRO LYS MET ILE GLY GLY ILE GLY GLY SEQRES 5 B 99 PHE ILE LYS VAL ARG GLN TYR ASP GLN ILE ILE ILE GLU SEQRES 6 B 99 ILE ALA GLY HIS LYS ALA ILE GLY THR VAL LEU VAL GLY SEQRES 7 B 99 PRO THR PRO VAL ASN ILE ILE GLY ARG ASN LEU LEU THR SEQRES 8 B 99 GLN ILE GLY ALA THR LEU ASN PHE HET NA A 501 1 HET CL A 512 1 HET 478 B 401 70 HET CL B 511 1 HET CL B 513 1 HET GOL B 801 6 HET GOL B 802 6 HETNAM NA SODIUM ION HETNAM CL CHLORIDE ION HETNAM 478 {3-[(4-AMINO-BENZENESULFONYL)-ISOBUTYL-AMINO]-1-BENZYL- HETNAM 2 478 2-HYDROXY-PROPYL}-CARBAMIC ACID TETRAHYDRO-FURAN-3-YL HETNAM 3 478 ESTER HETNAM GOL GLYCEROL HETSYN 478 AMPRENAVIR HETSYN GOL GLYCERIN; PROPANE-1,2,3-TRIOL FORMUL 3 NA NA 1+ FORMUL 4 CL 3(CL 1-) FORMUL 5 478 C25 H35 N3 O6 S FORMUL 8 GOL 2(C3 H8 O3) FORMUL 10 HOH *291(H2 O) HELIX 1 1 GLY A 86 THR A 91 1 6 HELIX 2 2 GLY B 186 ILE B 193 1 8 SHEET 1 A 4 GLN A 2 ILE A 3 0 SHEET 2 A 4 THR B 196 ASN B 198 -1 O LEU B 197 N ILE A 3 SHEET 3 A 4 THR A 96 ASN A 98 -1 N ASN A 98 O THR B 196 SHEET 4 A 4 GLN B 102 ILE B 103 -1 O ILE B 103 N LEU A 97 SHEET 1 B 8 TRP A 42 GLY A 49 0 SHEET 2 B 8 GLY A 52 ILE A 66 -1 O GLN A 58 N LYS A 43 SHEET 3 B 8 HIS A 69 VAL A 77 -1 O ALA A 71 N ILE A 64 SHEET 4 B 8 THR A 31 ILE A 33 1 N ILE A 33 O LEU A 76 SHEET 5 B 8 ILE A 84 ILE A 85 -1 O ILE A 84 N VAL A 32 SHEET 6 B 8 GLN A 18 LEU A 24 1 N LEU A 23 O ILE A 85 SHEET 7 B 8 LEU A 10 ILE A 15 -1 N ILE A 13 O LYS A 20 SHEET 8 B 8 GLY A 52 ILE A 66 -1 O GLU A 65 N LYS A 14 SHEET 1 C 8 LYS B 143 GLY B 149 0 SHEET 2 C 8 GLY B 152 ILE B 166 -1 O GLN B 158 N LYS B 143 SHEET 3 C 8 HIS B 169 VAL B 177 -1 O HIS B 169 N ILE B 166 SHEET 4 C 8 VAL B 132 ILE B 133 1 N ILE B 133 O LEU B 176 SHEET 5 C 8 ILE B 184 ILE B 185 -1 O ILE B 184 N VAL B 132 SHEET 6 C 8 GLN B 118 LEU B 124 1 N LEU B 123 O ILE B 185 SHEET 7 C 8 LEU B 110 ILE B 115 -1 N ILE B 113 O LYS B 120 SHEET 8 C 8 GLY B 152 ILE B 166 -1 O GLU B 165 N LYS B 114 LINK O ASP A 60 NA NA A 501 1555 1555 2.42 LINK NA NA A 501 O HOH A1128 1555 1555 2.29 LINK NA NA A 501 O HOH A1131 1555 1555 2.33 LINK NA NA A 501 O HOH A1129 1555 1555 2.33 LINK NA NA A 501 O HOH A1130 1555 1555 2.41 LINK NA NA A 501 O HOH A1132 1555 1555 2.76 SITE 1 AC1 6 ASP A 60 HOH A1128 HOH A1129 HOH A1130 SITE 2 AC1 6 HOH A1131 HOH A1132 SITE 1 AC2 4 THR A 74 ASN A 88 HOH A1150 ARG B 141 SITE 1 AC3 29 LEU A 23 ASP A 25 GLY A 27 ALA A 28 SITE 2 AC3 29 ASP A 29 ASP A 30 VAL A 32 GLY A 48 SITE 3 AC3 29 GLY A 49 ILE A 50 PRO A 81 VAL A 82 SITE 4 AC3 29 HOH A1001 HOH A1023 HOH A1146 HOH A1148 SITE 5 AC3 29 ASP B 125 GLY B 127 ALA B 128 ASP B 129 SITE 6 AC3 29 ASP B 130 VAL B 132 GLY B 148 GLY B 149 SITE 7 AC3 29 ILE B 150 PRO B 181 ILE B 184 HOH B1002 SITE 8 AC3 29 HOH B1156 SITE 1 AC4 2 HOH A1277 TRP B 106 SITE 1 AC5 3 THR B 174 ASN B 188 HOH B1162 SITE 1 AC6 10 GLN A 18 SER A 37 THR B 112 GLU B 165 SITE 2 AC6 10 ALA B 167 GLY B 168 GOL B 802 HOH B1137 SITE 3 AC6 10 HOH B1138 HOH B1139 SITE 1 AC7 11 GLN A 18 MET A 36 SER A 37 THR B 112 SITE 2 AC7 11 GLU B 165 ALA B 167 GLY B 168 GOL B 801 SITE 3 AC7 11 HOH B1137 HOH B1138 HOH B1139 CRYST1 58.107 85.971 46.420 90.00 90.00 90.00 P 21 21 2 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.017210 0.000000 0.000000 0.00000 SCALE2 0.000000 0.011632 0.000000 0.00000 SCALE3 0.000000 0.000000 0.021542 0.00000